6127.HK
603127.SHG

Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), said on Wednesday its revenue fell 15.5% to 486 million yuan ($68.3 million) in the third quarter, while its net profit tumbled 58% to 99.44 million yuan.

The company reported a net loss of 70.31 million yuan for the first three quarters of the year, reversing a profit of 328 million yuan in the same period of last year, mainly due to intensified competition in the industry, falling sales and a declining gross margin, as well as a drop in the fair value of its biological assets.

Joinn’s Hong Kong-listed shares rose 1.7% to HK$8.99 in early Thursday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Middle East expansion charges up Zhida’s stock

Shares of the EV charger maker, whose backers include BYD, jumped nearly 10% after announcing its latest expansion plan Key Takeaways: Zhida plans to enter the Middle East, targeting Saudi…